Bull Harbor Capital LLC Buys Shares of 2,066 Regeneron Pharmaceuticals, Inc. $REGN

Bull Harbor Capital LLC purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the first quarter, HoldingsChannel.com reports. The fund purchased 2,066 shares of the biopharmaceutical company’s stock, valued at approximately $1,596,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. increased its stake in Regeneron Pharmaceuticals by 0.3% in the 4th quarter. Vanguard Group Inc. now owns 9,075,153 shares of the biopharmaceutical company’s stock valued at $7,004,838,000 after purchasing an additional 26,884 shares in the last quarter. Dodge & Cox boosted its position in Regeneron Pharmaceuticals by 1.0% during the fourth quarter. Dodge & Cox now owns 4,596,358 shares of the biopharmaceutical company’s stock worth $3,547,791,000 after purchasing an additional 45,513 shares in the last quarter. Franklin Resources Inc. boosted its position in Regeneron Pharmaceuticals by 4.4% during the fourth quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company’s stock worth $1,975,990,000 after purchasing an additional 106,861 shares in the last quarter. Nuveen LLC boosted its position in Regeneron Pharmaceuticals by 71.1% during the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock worth $1,551,858,000 after purchasing an additional 835,240 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in Regeneron Pharmaceuticals by 142.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after purchasing an additional 1,144,887 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Potentially solid quarterly results: Investors are looking for continued growth from Dupixent, Eylea HD and Libtayo, along with updates on buybacks and Regeneron’s development pipeline. The prior quarter showed strong momentum, with revenue rising 19% year over year and EPS exceeding analyst expectations. Regeneron To Report Earnings Tomorrow
• Positive Sentiment: Partnered Arcalyst momentum: Kiniksa Pharmaceuticals exceeded second-quarter expectations, supported by sales of Arcalyst, which is partnered with Regeneron. The update may reinforce confidence in the commercial performance and royalty contribution of the collaboration, although the impact on REGN is indirect. Kiniksa Tops Q2 Estimates on Regeneron-Partnered Arcalyst
• Neutral Sentiment: Earnings are the next major catalyst: Regeneron is scheduled to report before the market opens Thursday. Investors will focus on product sales, full-year guidance, pipeline commentary and management’s response to the recent clinical setback. Regeneron to Announce Earnings on Thursday
• Negative Sentiment: Failed melanoma trial and litigation overhang: Multiple law firms announced or promoted securities class actions alleging that Regeneron and executives misled investors about the Phase 3 Fianlimab-Libtayo trial, including its protocol changes and clinical differentiation. The trial failure reportedly caused a sharp selloff and an approximately $11 billion loss in market value. The lawsuits themselves may not create an immediate cash liability, but they add reputational, legal and pipeline risk. Investors have until September 14, 2026, to seek lead-plaintiff status. Regeneron Investor Alert

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

REGN has been the subject of a number of research analyst reports. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating for the company in a research report on Tuesday, July 7th. Royal Bank Of Canada decreased their price objective on shares of Regeneron Pharmaceuticals from $707.00 to $696.00 and set a “sector perform” rating on the stock in a research report on Tuesday, July 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Leerink Partners restated a “market perform” rating and set a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. Finally, Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $787.88.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $695.42 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The company has a market capitalization of $73.52 billion, a price-to-earnings ratio of 16.94, a PEG ratio of 27.77 and a beta of 0.24. The company’s 50 day simple moving average is $638.74 and its 200 day simple moving average is $711.76. Regeneron Pharmaceuticals, Inc. has a 1 year low of $541.00 and a 1 year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, topping the consensus estimate of $8.91 by $0.56. The firm had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.48 billion. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% on a year-over-year basis. During the same period in the previous year, the company earned $8.22 EPS. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 2.06 EPS for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.